Education
About Us
Working with TipRanks
Follow Us
Cnbx Pharmaceuticals Inc (DE:8C80)
:8C80
8C80 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€3.40 - €3.88
Previous CloseN/A
Volume19.00
Average Volume (3M)19.00
Market Cap
€11.11K
Enterprise ValueN/A
Total Cash (Recent Filing)$45.67K
Total Debt (Recent Filing)$1.40M
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,196,841
10 Day Avg. Volume19
30 Day Avg. Volume19
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
8C80 FAQ
What was Cnbx Pharmaceuticals Inc’s price range in the past 12 months?
Cnbx Pharmaceuticals Inc lowest stock price was €3.40 and its highest was €3.88 in the past 12 months.
What is Cnbx Pharmaceuticals Inc’s market cap?
Cnbx Pharmaceuticals Inc’s market cap is €11.11K.
When is Cnbx Pharmaceuticals Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cnbx Pharmaceuticals Inc’s earnings last quarter?
Currently, no data Available
Is Cnbx Pharmaceuticals Inc overvalued?
According to Wall Street analysts Cnbx Pharmaceuticals Inc’s price is currently Overvalued.
Does Cnbx Pharmaceuticals Inc pay dividends?
Cnbx Pharmaceuticals Inc does not currently pay dividends.
What is Cnbx Pharmaceuticals Inc’s EPS estimate?
Cnbx Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cnbx Pharmaceuticals Inc have?
Cnbx Pharmaceuticals Inc has 4,196,841 shares outstanding.
What happened to Cnbx Pharmaceuticals Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cnbx Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in DE:8C80
---
Company Description
Cnbx Pharmaceuticals Inc
CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it develops Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.
---
Technical Analysis
Salarius Pharmaceuticals
―
Quoin Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Onconetix
―
---